Cyclophilin A (CyPA) is a 17 kDa, ubiquitously expressed multifunctional protein that possesses peptidylprolyl cis-trans isomerase activity and scaffold function. Its expression is increased in inflammatory conditions including rheumatoid arthritis, autoimmune disease and cancer. Intracellular CyPA regulates protein trafficking, signal transduction, transcription regulation and the activity of certain other proteins. Secreted CyPA activates cardiovascular cells resulting in a variety of cardiovascular diseases; including vascular remodeling, abdominal aortic aneurysms formation, atherosclerosis, cardiac hypertrophy and myocardial ischemic reperfusion injury. (J Korean Soc Hypertens 2011;17(4):133-147)
Introduction
Oxidative stress resulting from increased reactive oxygen species (ROS) formation contributes to the pathogenesis of cardiovascular diseases. Changes in vascular redox state are a common pathway involved in the pathogenesis of atherosclerosis, aortic aneurysms, vascular restenosis and ischemic reperfusion injury. ROS promotes vascular smooth muscle (VSMC) growth in part by increasing cell proliferation, hypertrophy and also inducing apoptosis in a concentration dependent manner. 1, 2) In addition, ROS modulates endothelial cells (EC) function by multiple mechanisms including increased inflammatory mediators and apoptosis to promote atherosclerosis. 3) Vascular ROS formation is stimulated by secreted factors such as Angiotensin II (AngII), 4) shear stress, 5) hypoxia, 6) mechanical stress. 7) In recent years Cyclophilin A (CyPA) has been described as having a key role in each of these cardiovascular pathologies. Understanding the mechanism(s) of CyPA in normal as well as diseased states is crucial for preventing cardiovascular disease progression.
Cyclophilins (CyPs) are members of the immunophilin family of proteins which possess peptidyl-prolyl cis-trans isomerase (PPIase) activity 8) that regulates cis-trans isomerization of Xaa-Pro peptide bonds and promote protein folding and assembly of multidomain proteins. In humans, there are at least 16 homologues of CyPs. Within the CyP family, CyPA is the most abundant and comprises approximately 0.1-0.6% of the total cytosolic proteins. 9) It was first purified from bovine thymocytes and described as the intracellular binding ligand of the immunosuppressant drug cyclosporine A (CsA). 10) CyPA regulates diverse cellular functions including protein folding, 11, 12) intracellular trafficking, 13) signaling transduction 14, 15) and transcription regulation 16) by its enzymatic activity as well as non-enzymatic scaffold function.
There have been several reports on the effects of CsA, a pharmacological inhibitor of CyPA PPIase activity, on neointima formation after balloon injury of rat or rabbit carotid. [17] [18] [19] [20] However, the results from these studies are contradictory with investigators finding that VSMC growth and neointima formation in animals that received CsA were increased, 19) not changed, 20, 21) or decreased. 18) Finally, a paper by Walter 17) showed that CsA protected EC from apoptosis. Clearly our data 22, 23) suggest that CyPA stimulates VSMC growth and promotes EC apoptosis. Our new data using CyPA transgenic and knockout mice substantiate a role for CyPA in neointima formation. 24) The reasons for the conflicting data are unclear, but may be related to CsA pharmacokinetics because its excretion is highly regulated by renal function, and dosing varied from 5 to 50 mg/kg/day in the studies.
Despite mounting evidence that cyclophilins serve multiple intracellular and extracellular functions, surprisingly little is known regarding their mechanisms of extracellular action ( Fig. 1 ). Several molecules have been proposed to serve as extracellular receptors for cyclophilins including CD147, [25] [26] [27] CD 14, 28) syndecan-1 (for CyPB), 29) heparan sulfate proteoglycans (for CyPB) 30) and CD91. 31) To date none of these proteins have unequivocally been proven to mediate the cellular events associated with CyPA. CD147 26) or extracellular matrix metalloproteinase inducer (EMMPRIN) 25) is a 50-60 kD integral membrane glycoprotein that is widely expressed. CyPA has been shown to be incorporated into the virions of human immunodeficiency virus type 1 (HIV-1) and enhances HIV-1 infection via interactions with CD147. 26) We have obtained antibodies to CD147 and think CD147 is unlikely to be the relevant 36, 37) CD4+ T cells reactive to the disease-related antigens oxi-dized low-density lipoproteins (LDL), HSP60, and chlamydia proteins have been cloned from human atherosclerotic lesions. 37, 38) When the antigen receptor of the T cell is ligated, an activation cascade results in the expression of a set of cytokines, cell-surface molecules, and enzymes.
Increased CyPA expression and secretion are observed in oxidative stress and inflammatory related conditions including cardiovascular diseases. However the precise mechanism of CyPA in cardiovascular diseases remains unclear. Therefore, better understanding of CyPA function may be promising therapeutic application in prevention, diagnosis and treatment in cardiovascular diseases.
In this review, we will focus on the current understanding of the role of CyPA in cardiovascular diseases.
CyPA as a secreted protein
CyPA is present in both the cytoplasm and nu- Recently data from our lab using ApoE -/mice showed CyPA was secreted from cardiac fibroblasts under oxidative stress conditions. AngII induced secretion of significant amounts of CyPA from ApoE -/cardiac fibroblast, 59) further indicating that CyPA is secreted by an active mechanism under oxidative stress conditions.
CyPA and posttranslational modification
The wide tissue distribution of CyPA, together with its high degree of conservation throughout evolution, suggests an essential role in cellular function. There are many types of post-translational modification of proteins, which can affect a protein's function, stability, degrada-tion and/or ability to interact with other proteins. CyPA is modified by several chemical groups in response to many different stimuli. Stimulation of chemokine receptor CXCR4 mediated phosphorylation of CyPA in HEK293T cells. 41) There is substantial data that ROS stimulates formation of acetylated CyPA (Acyl-CyPA).
Following oxidative stress, CyPA underwent glutathionylation on Cys52 and Cys62 residues that induced structural changes resulting in regulation of T cell function. 60) Glutathionylated CyPA was also observed in oxidatively stressed hepatocytes and hepatoma cells. 61) Furthermore in the mouse model for amyotrophic lateral sclerosis, in which oxidative stress is induced (by mutating SOD1 to make it inactive), acyl-CyPA was highly expressed. 62 
CyPA and vascular remodeling
Vascular remodeling is a consequence of the interaction between endothelial cells and vascular smooth muscle cells in response to hemodynamic changes. [64] [65] [66] Smooth muscle cell proliferation, migration and collagen syn-thesis are the key players in neointima formation which determines intima-media thickening of the vascular wall. [67] [68] [69] [70] [71] Accumulating evidence suggests that oxidative stress and inflammation are strongly correlated with neointima formation and vascular remodeling. [72] [73] [74] [75] Alternation in blood flow, growth factors and cytokines are important factors regulating oxidative stress and inflammation in neointima formation. [76] [77] [78] [79] [80] Oxidative stress causes VSMC growth and proliferation by regulating intracellular second messengers and downstream signaling pathways such as mitogen activated protein kinase, protein tyrosine kinase and phosphatase.
49, [81] [82] [83] [84] [85] [86] Interestingly, CyPA has been reported as an autocrine growth factor in VSMC. 23 It has been reported that CyPA has strong chemotactic activity for neutrophils, eosinophils and monocytes. 96, 97) Surprisingly, AngII-induced secretion and expression of cytokines and ckemokines from VSMC were dramatically inhibited in Ppia -/in compared with WT mice 54) suggesting CyPA may regulate cell migration by enhancing syn-thesis and secretion of chemotactic factors. It is also possible that secreted CyPA directly binds with CyPA receptor on the target cells.
CyPA and AngII-induced abdominal aortic aneurysm formation
The weakening, dilation and occasionally rupturing of the vessel wall characterize AAA. The key mechanisms of AAA development include chronic inflammation of aortic wall, 98) oxidative stress, [99] [100] [101] increased local production of proinflammatory cytokines and increased activities of Matrix Metallloproteinases (MMPs). 102) AAA development and rupture depend on VSMC-derived MMP2 103) and macrophage derived-MMP9 104) which are activated by membrane type-1 MMP (MT1-MMP). 105) AngII is an important growth factor for the production of ROS, 53) generation of inflammatory cytokines, 106, 107) and the secretion and activation of MMPs. 108) It is well documented that MMP expression and activation are strongly dependent on ROS 109, 110) were infused with AngII (1,000 ng/min/kg for 28 days).
We found that AngII-induced AAA formation was significantly reduced in DKO mice compared to ApoE -/controls with a concomitant increase in survival rate.
Deletion of CyPA prevented AngII-dependent ROS production and pro-MMP2 activation/secretion in VSMC suggesting that CyPA was crucial for ROS and MMP2 regulation in AAA development.
54)

CyPA and atherosclerosis
Atherosclerosis, chronic inflammation of medium and large arteries, leads to serious complications of car-diovascular diseases including acute myocardial infarction, aneurysm formation and stroke. [111] [112] [113] Atherosclerosis is initiated by the activation of EC leading to expression of adhesion molecules for inflammatory cells. 3) In addition, these activated EC facilitate the passage of lipid components in the plasma, such as LDL. 37 In addition CyPA inhibited eNOS expression, an important regulator of NO production for vascular homeostasis, 3) by suppression of the key transcription factor Kruppel-like factor 2 (KLF-2). This suggests that intracellular CyPA is also an important mediator of atherosclerosis by regulating gene transcription.
CyPA and cardiac hypertrophy
Cardiac hypertrophy is a fundamental response of cardiac cells to common clinical disorders such as arterial hypertension, valvular heart disease, myocardial infarction, cardiomyopathy, and congenital heart disease. 119) AngII plays a key role in many physiological and pathological processes in cardiac cells, including cardiac hypertrophy. 120) Therefore, understanding the molecular mechanisms responsible for AngII-mediated myocardial pathophysiology will be critical to developing new therapies for cardiac dysfunction. 121) One important mechanism now recognized to be involved in AngII-induced cardiac hypertrophy is ROS production, 122, 123) but the precise mechanism by which ROS cause hypertrophy remains unknown.
Our recent study provides strong mechanistic evidence of synergy between CyPA and AngII to increase ROS generation. 54) Since ROS stimulate myocardial hypertrophy, matrix remodeling, and cellular dysfunction, 124) we tested the hypothesis that CyPA enhances AngII-in-duced cardiac ROS production, and therefore cardiac hypertrophy. To examine the involvement of CyPA in the process of the cardiac hypertrophy, we used the AngII-infusion approach, a well-established mouse model to study CyPA has important roles in the immune system and it is a well described regulator of T lymphocyte functions. 15) It is relevant to note that the primary sources of CyPA responsible for cardiac hypertrophy were likely cells in the heart and not inflammatory cells, because transplantation with Ppia +/+ bone marrow cells still caused less cardiac hypertrophy in ApoE -/-Ppia -/compared to ApoE -/mice. We demonstrated that AngII-induced fibrosis and bone marrow-derived cell migration were much more pronounced in the perivascular region than in the myocardial interstitial space, findings consistent with recent reports. 125) These data suggest the importance of cardiac CyPA for recruitment of bone marrow-derived cells to perivascular tissues to create an environment that is pro-hypertrophic.
CyPA and myocardial ischemic reperfusion injury
Reperfusion therapy by coronary angioplasty or thrombolysis for acute myocardial ischemia (AMI) patients causes serious complications called ischemic/reperfusion injury (I/R injury) in which reversible ischemic tissue changes to irreversible tissue injury. [126] [127] [128] It has been reported that increased ROS production in I/R injury by coronary EC and circulating phagocytes enhance degradation of NO and expression of adhesion molecules in EC, resulting in inflammatory cell recruitment to injuried tissue. [129] [130] [131] [132] CyPA has been recognized as a proinflammatory cytokine which activate EC 22, 56, 118) 
